Changes in cerebrospinal fluid (CSF) biomarkers reflecting amyloid pathology (Aβ42) and neurodegeneration [total tau (t-tau) and phosphorylated tau (p-tau)] occur early in the course of AD and are increasingly implicated in the early and predictive diagnosis of AD [4, 5]. The gene discussed is MAPT; the disease is Alzheimer disease.